Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds
Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. While progression-free survival and other short-term measures slightly

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. Judith Cohen says:

    another question should hormone therapy be accompanied with other medications. Is molecular profiling important for prostate cancer victims?

    • Magdalena Kegel says:

      Hi Judith,
      As far as I am aware molecular profiling has yet to be established in prostate cancer clinical management. I am, however, not an oncologist and do not have insight into clinical practice matters.

    • Adrian Otto says:

      Hi Judith, I think the choice of the medical treatment is basically taken on the basis of the patient’s condition suffering with the disease. Though, as you mentioned the hormone therapy for the treatment of prostate cancer could be used as an alternative along with the other regular treatments like chemotherapy, radiation therapy Suffolk, immunotherapy, etc. If somebody is diagnosed with prostate cancer, there is no need to worry about anything. Just contact your oncologist and go for the best Prostate cancer treatment options Long Island ( http://www.advancedradiationcenters.com/cancers/prostate-cancer/ ) available for you. Get the accurate treatment at the best radiation Therapy New York and live life happily.

Leave a Comment

Your email address will not be published. Required fields are marked *